In this work, we studied a series of carfentanyl amide-based opioid derivatives targeting the mu opioid receptor (μOR) and the delta opioid receptor (δOR) heteromer as a credible novel target in pain management therapy. We identified a lead compound named that exhibits high G-protein activity at μ-δ heteromers compared to the homomeric δOR or μOR and low β-arrestin2 recruitment activity at all three. Furthermore, exhibits distinct signaling profile, as compared to the previously identified agonist targeting μ-δ heteromers, CYM51010. Pharmacological characterization of supports the utility of this compound as a molecule that could be developed as an antinociceptive agent similar to morphine in rodents. characterization reveals that maintains untoward side effects such as respiratory depression and reward behavior; together, these results suggest that optimization of is necessary for the development of therapeutics that suppress the classical side effects associated with conventional clinical opioids.